ANNUAL REPORT JULY 2016-2017

IN REMEMBERANCE OF MARK WAINBERG

Professor Mark Wainberg was a pioneer for HIV research, advocacy and scientific advancement. In April 2017, he died at the age of 71 in Bal Harbour, Florida.

Prof Wainberg is widely known for his part in the 1989 discovery that the drug 3TC could be used to treat HIV infection. He was currently serving as the head of AIDS research at the Lady Davis Institute for Medical Research (LDI), Director of the McGill University AIDS Centre located at the LDI, and Professor of Medicine and of Microbiology and Immunology at McGill University in Montreal. In Canada, his home, he was inducted into the Canadian Medical Hall of Fame for his accomplishments.

He served as president at the IAS from 1998 to 2000, a period which he was highly recognized and admired for his part in the historic and transformative XIII International AIDS Conference in 2000 that was held in Durban, South Africa.

In addition to his presidency, one of Mark’s biggest contributions to the IAS was founding the Journal of the International AIDS Society (JIAS) in 2004, which he was still supporting as one of its three Editors-in-Chief. His role with JIAS was evidence of his deep belief in and commitment to supporting emerging researchers and providing platforms to showcase their work. Mark's vision of JIAS did not only include a wide dissemination of research findings relevant for ending the HIV epidemic, but a more far-reaching goal of mentorship for new generations of researchers and scientists.

Mark was a leader, mentor and close friend to the IAS, our staff and our community. The impact of his work will live on through the millions of people accessing HIV treatment and those of us who were lucky enough to know him.

LETTER FROM THE EXECUTIVE DIRECTOR

This letter is an excerpt from the 2017 IAS Annual Letter, read the full letter here.

As corners of the planet shift towards nationalism and xenophobia, we wonder where the future of our global cause lies.

As 2017 unfolds, our community is anxious and concerned. Political and societal changes continue to upend our expectations and generate uncertainty about what is ahead of us. We worry about human rights, the plight of refugees and migrants, progress towards gender equality, and the strength of our commitment to each other as human beings.

Deeply wrapped up in all of this is our fight against HIV – a disease that has shown itself adept at exploiting the very changes that seem to be dominating our world.

As corners of the planet shift towards nationalism and xenophobia, we wonder where the future of our global cause lies. Is the progress we have made against the greatest pandemic of our time slipping through our hands?

No, it’s not – at least not yet.

In the midst of this anxiety and uncertainty, we’ve seen action and defiance against rolling back hard-won gains. The millions of people who participated in Women’s Marches around the world in January are proof that apathy doesn’t rule, that a collective determination is there to resist a new world order that demonizes and isolates those in need.

Our movement has shown that we know how to make history, not merely observe or survive it. That is our strength. We are not history’s passengers. We are its conductors.

Our movement has shown that we know how to make history, not merely observe or survive it. That is our strength. We are not history’s passengers. We are its conductors.

And let’s remember: 2016 was a remarkable year for our work. In those 12 months: the Global Fund to Fight AIDS, Tuberculosis and Malaria was replenished; the world demonstrated its political commitment at all levels to fight AIDS at the United Nations General Assembly High-Level Meeting on Ending AIDS; and we returned to Durban for the 21st International AIDS Conference (AIDS 2016) for a, yet again, historic meeting on HIV and AIDS.

Continued progress can be seen across our work – in the development of long-acting antiretrovirals; the launch of the first large-scale HIV vaccine trial in southern Africa in nearly 10 years; the more than 18 million people receiving HIV treatment; and growing momentum for the scale up of HIV.

The return to Durban reunited and rejuvenated the AIDS community, reminding us how far we have come from the birth of the treatment access movement in 2000. But Durban was also a wake-up call. UNAIDS released an alarming report detailing how our prevention efforts have faltered. And a separate report on funding trends gave rise to genuine fears that international donors are moving on from AIDS. These signs of trouble came only weeks after the global community wavered in its commitment to address the needs of key populations at the UN High-Level Meeting.

If 2016 served as a wake-up call from complacency and premature congratulations, 2017 must be the year when the HIV community confronts our challenges and renews our determination to grasp the historic opportunities that scientific research and community leadership have given us.

In July this year, we reconvene for the 9th IAS Conference on HIV Science (IAS 2017) in Paris, the home of some of the most important breakthroughs in HIV science. The meeting offers a critical opportunity for our community to resist a world turning inward, and to demand that at this pivotal moment – when we can actually see the light at the end of the tunnel – we must keep faith with the tens of millions of people living with and affected by HIV.

Sincerely


Owen Ryan
IAS Executive Director

MEMBERSHIP

The mission of the International AIDS Society (IAS) is to lead collective action on every front of the global HIV response through its membership base, scientific authority, and convening power. Together, with our members we advocate and drive urgent action to reduce the global impact of HIV.

The #IASONEVOICE membership campaign continued for the second year, highlighting the key topics most important to IAS members, sharing their personal perspectives from working and volunteering on all fronts of the HIV response. This year, the campaign featured the following stories and opinions:

From discovery to a cure: A conversation with Françoise Barré-Sinoussi
From trans rights to the right HIV response
HIV prevention in the hands of women
Standing up for science
Testing on the front lines
Living with HIV, then and now
A country on the brink

For more stories visit: www.iasociety.org/Membership/IASONEVOICE/Stories

By the numbers

Between July 2016 and July 2017, the IAS membership base reached 11,035 individuals from more than 160 countries. Working at all levels of the global HIV response, IAS members include researchers, clinicians, service providers, policymakers, people living with HIV and community advocates. The following provides a breakdown of our membership from this calendar year.






Translating the science

The IAS Educational Fund was established in an effort to make dynamic, scientific fora more accessible to IAS Members and their communities. In addition to providing direct support to clinicians and other healthcare providers to attend our best-in-class global meetings, the IAS convenes smaller meetings around the world, targeted at healthcare workers, advocates and policymakers to provide access to the latest science and opportunities to question how that information impacts local epidemics. During these smaller meetings, key scientific and policy content from the International AIDS Conferences and IAS Conferences on HIV Science are discussed, as well as the implementation science priorities for policy and programme improvements. Participants explore strategies for bridging the gap between HIV science and programme implementation, and the meetings are also an opportunity for participants to share scientific research results from local treatment and prevention experiences. For the second year, the IAS Educational Fund continued this effort connecting research and practice from a global level to a local context, through a series of six regional meetings.

ABUJA, NIGERIA / 26-28 OCTOBER 2016
The science-driven HIV response in Nigeria – Translating best practices into policy service delivery

This IAS Educational Fund regional meeting took place in Nigeria in collaboration with the West African Infectious Diseases Institute (WAIDI). John Idoko, a new member of the IAS Governing Council, assisted in organizing and leading the meetings. The symposium on 27 October, Building consensus – Strategies for bridging the gap between HIV science and programme implementation, brought together more than 200 participants.

DAKAR, SENEGAL / 27, 29 & 30 NOVEMBER 2016
A scientific response to HIV in Senegal – Translating best practices into policy and implementation

This IAS Educational Fund meeting was organized in collaboration with the Conseil national de lutte contre le sida and the Institut de recherche en santé, de surveillance épidémiologique et de formation, led by former IAS Governing Council member Souleymane Mboup. The meetings took place prior to the first “HIV science days” in Senegal and were carried out in French. The symposium on 29 November, discussing strategies to bridge the gap between science and programme implementation in Senegal, was attended by more than 150 participants from the HIV sector.

CASABLANCA, MOROCCO / 15-17 MARCH 2017
A scientific response to HIV in North Africa – Translating best practices into policies

This IAS Educational Fund meeting was organized in collaboration with the Association de lutte contre le sida and was carried out in French. The meeting was co-chaired by IAS Governing Council member Bruno Spire. The meeting included participants from Morocco, Algeria, Tunisia and Mauritania. The symposium on 16 March addressed how to translate scientific advancements into concrete actions, from theory to practice. It was attended by more than 100 participants.

RIO DE JANEIRO, BRAZIL / 5 APRIL 2017
Science and community in the response to HIV in Latin America and the Caribbean

This IAS Educational Fund meeting took place prior to the congress on HIV & Hepatitis in the Americas and was carried out in Portuguese, Spanish and English. The meeting was co-chaired by IAS President Linda-Gail Bekker and IAS Governing Council member Mauro Schechter. The meeting brought together 50 participants from the Latin American and Caribbean region.

MONTREAL, CANADA / 6 APRIL 2017
Leaving no one behind – Building on the strength of Indigenous communities to collectively broaden the response to HIV and hepatitis C in Canada

This IAS Educational Fund meeting was supported by the Canadian HIV Trials Network of the Canadian Institutes of Health Research, the Canadian Network on Hepatitis C, the National Collaborating Centre for Infectious Diseases, the Canadian Aboriginal AIDS Network, and the Research Institute of McGill University Health Centre. IAS Governing Council member Marina Klein co-chaired this ancillary event to the Canadian Association for HIV Research conference (CAHR 2017), focusing on Indigenous communities.

NAIROBI, KENYA / 28-30 May 2017
Translating the science to end new HIV infections in Kenya – Perspectives, practices and lessons

IAS Governing Council members Kenneth Ngure and Alex Muganga Muganzi were co-chairs during this meeting, which included participants from across the Eastern African region. The meetings were organized in collaboration with the National AIDS Control Council (NACC) and took place in conjunction with the 4th Maisha HIV and AIDS Conference. Over 600 participants from the HIV sector attended the symposium on 29 May.

Capacity building

HIV science evolves rapidly, requiring constant interpretation, translation and knowledge exchange. This year, the IAS committed to promoting greater understanding of HIV science and policy in order to build the skills and resources that are needed to end the epidemic – retaining a global perspective that is relevant at a local level.

As part of this commitment, the IAS published the AIDS 2016 Knowledge Toolkits. These are the first in a series of knowledge toolkits developed exclusively for IAS members, highlighting important scientific advancements and innovative research presented at its conferences. The toolkit series offers adaptable PowerPoint presentations with an easy navigation system and printable speaker notes covering the five scientific tracks presented at AIDS 2016.

This series will continue with IAS 2017 Knowledge Toolkits providing more research and tools for IAS members.

Learn how to access these toolkits and other exclusive IAS member benefits here:
www.iasociety.org/Membership/
Become-a-Member/Benefits

IAS General Members’ Meeting

To build a strong, informed and connected IAS membership body, the IAS convenes the annual IAS General Members’ Meeting.

On 21 July 2016, the IAS General Members’ Meeting took place during AIDS 2016 in Durban, South Africa. More than 400 IAS members attended the meeting chaired by then IAS President Chris Beyrer.

The full meeting can be viewed at
www.youtube.com/watch?v=1Tk6p4Bu5mA.

HIV PROGRAMMES AND ADVOCACY

This year the IAS launched its HIV Programmes and Advocacy operational strategy for 2017-2020, to expand its voice and contribution to the broader HIV response. The strategy instigates action across three linked domains: policy, research and structural barriers.

Policy

Influence global and national HIV policy and bridge gaps between the HIV response and the broader integrated health landscape

Research

Inspire HIV research targeting scientific gaps in strategic priority areas

Structural barriers

Instigate action to remove structural barriers and address human rights violations that prohibit access to and uptake of comprehensive HIV services for selected populations and communities

Within the new advocacy strategy there is an emphasis on three cross-cutting issues: human rights, gender and youth, which is threaded throughout IAS advocacy and programmatic work.

The portfolio

The activities and work of the new strategy are carried out under the following IAS programmes and initiatives. Through advocacy, capacity building and collaboration the IAS programmes promote the implementation of evidence-informed and human rights-based strategies to improve the lives of people living with and most vulnerable to HIV.


Towards an HIV Cure

The toolbox of interventions for fighting the global HIV pandemic has grown exponentially since the discovery of the virus, but a cure has remained beyond our grasp. In recent years, however, research to develop a cure for HIV or long-term remission has made promising progress, galvanizing researchers, advocates, and community members alike. To that end, the mission of the Towards an HIV Cure initiative is to drive concerted efforts to accelerate global scientific research and engagement towards a cure for HIV.

Featured work - Research

Convened a multidisciplinary International Scientific Working Group of leading experts in basic, clinical and social science, ethicists and global stakeholders to develop the IAS Global Scientific Strategy: Towards an HIV Cure 2016, published in Nature Medicine in July 2016.


Industry Liaison Forum

The last decade has been marked by rapid advances in HIV research, leading to the introduction of new and more efficacious and client-friendly interventions for diagnosing and treating people living with HIV and preventing the further spread of the virus. Critical gaps remain in the development and expedient delivery of medical innovations to the people that most need them across the HIV cascade. The IAS Industry Liaison Forum (ILF) works to promote and facilitate the full contribution of the biomedical industry to the global HIV response by catalysing dialogue, engagement and action to address barriers along the HIV care continuum. It focuses on two main areas: paediatric HIV and regulatory affairs.

Featured work - Policy

Carried out a consultation with the diagnostics industry involving 14 manufacturers, to improve the WHO prequalification of in vitro diagnostics with regards to scope, processes, timelines, transparency, communication and financing.


Collaborative Initiative for Paediatric HIV Education and Research (CIPHER)

Despite notable progress in reducing vertical transmission of HIV, children and adolescents living with HIV remain significantly disadvantaged regarding access to treatment. In recent years, the adolescent group has seen a 50% increase in AIDS-related mortality compared with a decrease of 30% globally. The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) aims to optimize clinical management and delivery of services to infants, children, and adolescents affected by HIV in resource-limited settings. Guided by a world-class Scientific Technical and Advisory Committee (STAC) of experts in paediatric HIV, CIPHER is designed to complement existing global initiatives and create partnerships to maximize investment in paediatric HIV research and improve paediatric health outcomes.

Featured work - Research

Awarded the largest round of paediatric research grants at AIDS 2016. The CIPHER Cohort Collaboration presented results from its first two studies on the duration of first-line ART in children and the global epidemiology of perinatally HIV-infected adolescents.


Journal of the International AIDS Society (JIAS)

Founded in 2004, JIAS is an open-access, PubMed- and Medline-indexed journal. JIAS articles are published only online and are free of charge to readers. The journal’s primary purpose is to provide an open-access platform for the generation and dissemination of evidence from a wide range of HIV-related disciplines, encouraging research from low- and middle-income countries. More specifically, JIAS encourages publications from the emerging field of implementation and operational research, which is not adequately covered by other international HIV journals. In addition, JIAS aims to strengthen capacity and empower less experienced researchers from resource-limited countries.

Featured work - Research

Published the special issue, HIV epidemics among transgender populations: The importance of a trans-inclusive response, to support HIV policies and programmes with the latest research and most current trans-specific knowledge.


Differentiated Care

To reach the UNAIDS 90-90-90 targets, new, differentiated approaches are needed to meet the diverse needs and expectations of all people living with HIV. Differentiated care, or differentiated service delivery, has been defined as “a client-centred approach that simplifies and adapts HIV services across the cascade, in ways that both serve the needs of PLHIV better and reduce unnecessary burdens on the health system”. The IAS Differentiated Care initiative is committed to supporting the scale-up of differentiated care through catalyzing country and community advocacy and amplifying global best practices, tools, and evidence to effectively reach the 37 million people worldwide in need of high-quality life-saving HIV care.

Featured work - Policy

Supported national policy uptake of differentiated antiretroviral treatment (ART) delivery in Zimbabwe, Swaziland and Tanzania. At a global policy level, co-hosted a consultation with the World Health Organization (WHO) and the United States President's Emergency Plan for AIDS Relief (PEPFAR).


HIV Co-Infections and Co-Morbidities

Among people living with HIV, morbidity and mortality is increasingly driven by co-infection with other diseases, including tuberculosis (TB) and hepatitis C (HCV), and co-morbidity with non-communicable diseases (NCDs). Successfully addressing the challenge of co-infections requires tackling the complexities of multiple epidemics, including reaching vulnerable populations and expanding access to new diagnostics and curative medicines. The IAS HIV Co-Infections and Co-Morbidities initiative will focus on three areas – HIV/HCV co-infection, HIV/TB co-infection, and HIV/NCDs co-morbidity – taking advantage of overlapping populations and service delivery needs of HIV and related co-infections and co-morbidities.

Featured work - Policy

TB 2016 galvanized political leadership for intensified implementation policies and an inspired new generation of TB activists and leaders. The 3rd International HIV/Viral Hepatitis Co-Infection Meeting advocated for increased diagnosis and treatment of viral hepatitis, particularly among people who inject drugs.


HIV Co-Infections and Co-Morbidities

The substantial gains made in the global fight against HIV in recent years have not been shared equally across all groups. Key populations—including men who have sex with men (MSM), transgender individuals, sex workers, and people who inject drugs (PWID)—are at an increased risk of HIV acquisition and experience higher rates of HIV prevalence compared to the general adult population. The Nobody Left Behind campaign is dedicated to bringing greater attention to the challenges faced by key populations and supporting efforts to remove barriers affecting their access to HIV prevention, treatment and care services.

Featured work - Structural barriers

Launched the Me and My Healthcare Provider campaign to address the stigma and discrimination often faced by key populations in healthcare settings, with the objective of improving access to quality HIV prevention, treatment and care services.


Adolescent HIV Treatment Coalition (ATC)

Hosted by the International AIDS Society, the Adolescent HIV Treatment Coalition (ATC) is a diverse community united in our advocacy to make quality treatment and care available for all adolescents living with HIV. ATC provides a collective voice promoting accountability in the HIV response to the realities of adolescent lives. We do this through calling attention to gaps, proposing solutions and working collaboratively on adolescent treatment issues.

To advance efforts to engage young people living with HIV in decision-making on issues that affect their lives, 40 young people from 19 countries representing networks of young people living with HIV met in Cape Town, South Africa, on 19 and 20 June. The Intergenerational Summit for Positive Youth Leadership was held with support from UNAIDS, the Adolescent Treatment Coalition and partners.

www.iasociety.org/Adolescent-HIV-Treatment-Coalition

Featured work - Structural barriers

Convened 25 regional and national networks of young people living with HIV and key stakeholders within the HIV response to better understand their needs and explore opportunities for leadership and collaboration among these networks and organizations.

Me and My Healthcare Provider Campaign

Me and My Healthcare Provider is a campaign that is part of the International AIDS Society’s (IAS) Nobody Left Behind initiative, which focuses on the broader needs of key populations affected by HIV – men who have sex with men (MSM), transgender people, sex workers and people who inject drugs. Me and My Healthcare Provider celebrates the many doctors, nurses, receptionists, pharmacists and other frontline healthcare providers who are #DoingTheRightThing by delivering quality HIV prevention, treatment and care services to key populations, often in the face of discriminatory laws, traditions and belief systems. The campaign is driven by key populations affected by HIV, giving them an opportunity to acknowledge the contributions of healthcare providers who have made a tangible difference in their lives.

In 2016, four healthcare providers from Belize, Cameron, Peru and Ukraine were recognised on the global stage of AIDS 2016 by Sir Elton John. The providers were nominated by the communities they serve and their stories were highlighted throughout the year to showcase the importance and impact of #DoingTheRightThing.

Youth Voices Campaign

Youth Voices is an advocacy campaign to support and amplify the voices of young people to influence policy makers, funders and healthcare providers to improve services for young people, including young people living with HIV and young key populations. The campaign focuses on encouraging youth leadership in community-based organizations; highlighting young people’s needs in the HIV response through films; and providing training, tools and resources to young people, including capacity development and networking opportunities at international meetings and conferences.

Under the work of the Youth Voices campaign, 10 organizations were awarded grants to increase their capacity for youth-led projects, and highlighted the stories of four young people working in or affected by HIV through the IAS Youth Voices campaign.

21ST INTERNATIONAL AIDS CONFERENCE (AIDS 2016)

The 21st International AIDS Conference (AIDS 2016) was hosted in Durban, South Africa, under the theme Access Equity Rights Now, on 18-22 July 2016. Held every two years, the International AIDS Conference is the largest conference on any global health or development issue. First convened during the peak of the AIDS epidemic in 1985, this conference continues to be the premier gathering for those working in the field of HIV, as well as for policymakers, people living with HIV and other individuals committed to ending the epidemic.

AIDS 2016 marked not only the passing of three decades since the first International AIDS Conference in 1985, but also a return to South Africa, specifically to Durban. The 13th International AIDS Conference (AIDS 2000) was convened in Durban in 2000; it was the first International AIDS Conference to be held in a resource-limited setting. AIDS 2000 was a catalyst for historic change, ushering in a global movement to bring life-saving antiretroviral treatment (ART) to resource-limited countries.

Sixteen years later, the HIV response has been remarkably transformed, but the struggle to ensure equal access to prevention and treatment for all is far from over. AIDS 2016 served as a landmark moment for leaders of the global HIV response to forge critical plans and hear the voices of those most affected: people living with HIV and the key populations affected by HIV.

The conference sparked a revitalized union between science and activism driven by a new generation of leaders. This was demonstrated by one of the largest youth participation levels ever at an International AIDS Conference, including its first youth ambassador programme.

By the numbers




By the headlines

“AIDS conference returns to a changed South Africa”

“Global AIDS gains ‘inadequate and fragile,’ UN chief says”

“Drugs almost eliminate risk of sex with HIV-positive partner, African study shows”

“Charlize Theron says not enough is being done to quell AIDS epidemic: 'It's time we face the truth' ”

“Researchers warn of no quick HIV cure”

 “Anti-HIV ring could offer good protection”

“Huge boom in teen HIV cases could cause epidemic to spiral”

“A cure for AIDS is no longer unthinkable”

“Elton John: LGBT people must be part of AIDS fight”

“AIDS scientists hail promising prevention study”

“Prince Harry and Elton John urge redoubling of efforts against HIV/AIDS”

Pre-conferences: A fresh approach

At AIDS 2016, the International AIDS Conference developed a fresh approach to the traditional pre-conference meeting agenda by integrating a series of independently organized meetings within the main conference venue. The new pre-conference programme was held over the weekend of 16 and 17 July, immediately preceding AIDS 2016, offering a more formal pre-conference programme to enhance the delegate experience.

The following official pre-conferences represented a diversity of scientific, technical and community interests:

  • Action + Access: Rights and Demands of Gay and Bisexual Men in the Global HIV Response
  • Towards an HIV Cure: Engaging the Community
  • Global HIV Clinical Forum: Integrase Inhibitors
  • Achieving Global AIDS Targets: What Will It Really Take?
  • In Our Voice: Positive Stories! Positive Teens! Positive Lives!
  • 3rd International HIV/Viral Hepatitis Co-Infection Meeting
  • No More Lip Service: Trans Access, Equity and Rights, Now!
  • TB2016
  • Nursing HIV 2016
  • The Positive Action for Children Fund Collaboration
  • UN 90-90-90 Target Workshop: A Vehicle for Knowledge Translation of Treatment as Prevention
  • Towards an HIV Cure Symposium
  • LIVING 2016: The Positive Leadership Summit

For more information on the scientific highlights, speakers and the overall evaluation of AIDS 2016, read the full conference report here: www.aids2016.org/ConferenceReport

GOVERNANCE

IAS Governing Council

The IAS Governing Council is the executive body of the IAS. It approves the annual budget and presents financial and other information to the IAS General Members’ Meeting at each International AIDS Conference and each IAS Conference on HIV Science.

From left to right:
President, Linda-Gail Bekker
President-Elect, Anton Pozniak
Treasurer, Celia DC Christie-Samuels
Immediate Past President, Chris Beyrer
Executive Director, Owen Ryan

Regional Representatives on the IAS Governing Council

AFRICA
Alex Muganga Muganzi - Regional Representative
Serge Paul Ehoilé
James G Hakim
Kenneth Ngure
LATIN AMERICA AND THE CARIBBEAN
Luis Soto-Ramirez - Regional Representative
Russell Pierre
Horacio Salomon
Mauro Schechter
ASIA AND THE PACIFIC ISLANDS
Adeeba Kamarulzaman - Regional Representative
Roy Chan
Sharon Lewin
Shuzo Matsushita
UNITED STATES AND CANADA
Kenneth Mayer - Regional Representative
Adaora Adimora
Judith Auerbach
Marina Klein
EUROPE
Jürgen Rockstroh - Regional Representative
Sergii Dvoriak
Bruno Spire
Stefano Vella
 

IAS Executive Committee

The IAS Executive Committee acts on behalf of the IAS Governing Council and provides effective oversight and review of the IAS’s operations and finances between governing council meetings. The committee also reviews and appraises the performance of the Executive Director.

The IAS Executive Committee consists of the president, president-elect, treasurer and one regional representative selected from the governing council members of each region, as well as the executive director as a non-voting member. The president may also invite other governing council members to executive committee meetings to participate in discussions of matters within their area of expertise.

FINANCIAL REPORTS

SUPPORTERS

Thank you to our July 2016-June 2017 supporters

We would like to thank our dedicated supporters, without whom we could not realize the impact of our work.

Abbott Molecular
AbbVie
Abt Associates
Aeras
l’Agence de recherche ANRS (France Recherche Nord & Sud Sida-HIV Hépatites)
Alere
amfAR - The Foundation for AIDS Research
Anglo American South Africa
ARK Diagnostics
Aspen Pharmacare
Aurobindo Pharma
Beckman Coulter
The Bill & Melinda Gates Foundation
bioLytical Laboratories
Brand South Africa
Bristol-Myers Squibb
Canada – Global Affairs
Canada – Public Health Agency of Canada
Capital for Good
Cepheid
Chevron
Cipla
Contravir
Discovery Health
Durban KZN Convention Bureau
ELMA Philanthropies
Elton John AIDS Foundation
European AIDS Clinical Society
Female Health Company
The Ford Foundation
The Foundation to Promote Open Society
Gilead Sciences
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Harmony Gold Mining Company
Hetero Labs

Human Sciences Research Council of South Africa
Imperial Group
Janssen Pharmaceutica
Johnson & Johnson
The Joint United Nations Programme on HIV/AIDS (UNAIDS)
The Kwazulu-Natal Provincial Government - Office of the Premier
Lupin
M·A·C AIDS Fund
Merck Sharp & Dohme
Mylan
The Netherlands - Ministry of Foreign Affairs
Omega Diagnostics
The OPEC Fund for International Development
Roche
Save the Children
Sidaction
South Africa - National Department of Health
South Africa - National Department of Science and Technology
South Africa - National Department of Social Development
South Africa - National Lotteries Commission
South Africa - The Health and Welfare Sector Education and Training Authority
South African Medical Research Council
Sweden - The Swedish International Development Cooperation Agency
Sysmex Partec
Treatment Action Group
U.S. National Institute of Allergy and Infectious Diseases
U.S. National Institute on Drug Abuse
U.S. National Institutes of Health - Office of the Director
UNITAID
United Nations Children’s Fund (UNICEF)
United Nations Development Programme (UNDP)
ViiV Healthcare
World Health Organization (WHO)

JOIN US

Become an IAS member
Join the collective voice of policy makers, researchers, scientists and community members to shape the global HIV response. Visit www.iasociety.org/membership to learn more about our work and the benefits of becoming a member.

Stay up-to-date
Join the IAS mailing list to receive the latest news, updates and announcements.

Spread the word & join the conversation
Follow us on social media to help amplify the work of the HIV response.

FACEBOOK: www.facebook.com/IASociety
INSTAGRAM: @IASociety
LINKEDIN: www.linkedin.com/company/international-aids-society
TWITTER: @IASociety
YOUTUBE: www.youtube.com/channel/UCqnJebKuVVpbTjCQcsLsI8g

Download the full report here